Recent Manufacturing Challenges Hospira has experienced quality assurance and regulatory issues, leading to the closure of several facilities and product recalls. This situation presents opportunities to offer advanced quality control solutions, supply chain optimization services, or regulatory compliance expertise.

Innovation in Biosimilars The company's launch of biosimilar products like infliximab indicates a focus on cost-effective biologics. Developing partnerships in biosimilar manufacturing, distribution, or patient access solutions could align well with Hospira's strategic expansion into biosimilars.

Sustainability Initiatives Hospira's introduction of PVC/DEHP-free IV bags demonstrates an emphasis on environmentally friendly products. There is potential to collaborate on sustainable packaging, eco-friendly medical device innovations, or waste reduction technologies.

Strategic Partnerships Existing collaborations with medical device companies, such as Smith Medical, highlight openness to joint ventures. Identifying complementary partnerships in infusion technology, safety device enhancements, or digital health solutions could drive growth.

Market Focus and Growth With a revenue range of up to 10 billion dollars and a significant presence in pharmaceutical manufacturing, Hospira offers opportunities for sales of advanced pharmaceutical ingredients, manufacturing technology, or service solutions aimed at streamlining production and ensuring compliance in a competitive market.